Stage IV Pancreatic Cancer AJCC v8 (DBCOND0112470)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04005690	Targeted Pathway Inhibition in Patients With Pancreatic Cancer	No drug interventions	treatment	0	recruiting
NCT04058964	Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer	No drug interventions	treatment	2	withdrawn
NCT04191421	Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer	No drug interventions	treatment	1 / 2	completed
NCT05685602	CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer	No drug interventions	treatment	1	suspended
NCT06398587	Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma	Albumin human Gemcitabine Onvansertib Paclitaxel	treatment	2	withdrawn
NCT05038254	Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events	No drug interventions	health_services_research	Not Available	recruiting
NCT03784677	A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors	Calcium SOR-C13	treatment	1	completed
NCT04132505	Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer	Binimetinib Hydroxychloroquine	treatment	1	recruiting
NCT04887805	Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	Lenvatinib Pembrolizumab	treatment	2	recruiting
NCT04514497	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	Camptothecin Elimusertib Irinotecan Topotecan	treatment	1	active_not_recruiting
NCT06454383	Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer	Cholestyramine Gemcitabine Leflunomide	treatment	1	recruiting
NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	Vidutolimod	treatment	1 / 2	terminated
NCT04858009	Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis	Albumin human Chloride ion Cisplatin Paclitaxel Platinum	treatment	2	recruiting
NCT04050085	SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer	Nivolumab Toll-like receptor 9	treatment	1	completed
NCT06115499	The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer	Albumin human Cisplatin Gemcitabine Paclitaxel	treatment	2 / 3	recruiting
NCT04616534	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	Elimusertib Gemcitabine	treatment	1	active_not_recruiting
NCT04975516	Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer	No drug interventions	treatment	2	recruiting
NCT03816358	Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer	Anetumab ravtansine Gemcitabine Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT04158635	Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer	Albumin human Bosentan Gemcitabine Paclitaxel	treatment	1	recruiting
NCT04115163	Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer	Albumin human Gemcitabine Paclitaxel	treatment	2	recruiting
NCT03033225	Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study	Verteporfin	treatment	2	completed
NCT04809766	Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT05554367	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	Binimetinib Palbociclib	treatment	2	recruiting
NCT04539808	NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer	Calcium Camptothecin Capecitabine Fluorouracil Irinotecan Leucovorin Levoleucovorin Losartan Oxaliplatin	treatment	2	recruiting
NCT03291938	IACS-010759 in Advanced Cancers	No drug interventions	treatment	1	completed
NCT04390243	Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation	Binimetinib Encorafenib	treatment	2	terminated
NCT05911243	Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT02671890	Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer	Disulfiram Gemcitabine	treatment	1	active_not_recruiting
NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer	Albumin human Gemcitabine Hydroxychloroquine Paclitaxel Paricalcitol	treatment	2	active_not_recruiting
NCT04821284	Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer	Albumin human Calcium Camptothecin Fluorouracil Gemcitabine Irinotecan Leucovorin Levoleucovorin Oxaliplatin Paclitaxel Platinum	treatment	1 / 2	recruiting
NCT04449679	Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study	No drug interventions	supportive_care	Not Available	completed
NCT03910387	Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer	Albumin human Gemcitabine Paclitaxel Telotristat ethyl	supportive_care	2	active_not_recruiting
NCT06381154	Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer	Fluorouracil Irinotecan Leucovorin Oxaliplatin Pembrolizumab Verteporfin	treatment	2	not_yet_recruiting
NCT01585805	Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Chloride ion Cisplatin Gemcitabine Platinum Veliparib	treatment	2	active_not_recruiting
NCT03925428	Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas	No drug interventions	treatment	1	withdrawn
NCT05053971	Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	No drug interventions	treatment	1 / 2	recruiting
NCT02983578	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	No drug interventions	treatment	2	active_not_recruiting
NCT03723915	Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer	No drug interventions	treatment	2	terminated
NCT04548752	Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations	No drug interventions	treatment	2	recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	No drug interventions	treatment	2	recruiting
NCT06043713	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	No drug interventions	treatment	1	recruiting
NCT04837118	Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study	No drug interventions	supportive_care	Not Available	active_not_recruiting
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	No drug interventions	treatment	1	terminated
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	No drug interventions	treatment	1	recruiting
NCT04233866	Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread	No drug interventions	treatment	2	active_not_recruiting
NCT03608631	iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation	No drug interventions	treatment	1	active_not_recruiting
NCT02595931	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	No drug interventions	treatment	1	active_not_recruiting
NCT05238831	SMMART Adaptive Clinical Treatment (ACT) Trial	No drug interventions	treatment	0	withdrawn
NCT05034627	Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer	No drug interventions	treatment	1	recruiting
NCT03432676	Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer	No drug interventions	treatment	2	withdrawn
NCT06206876	FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	No drug interventions	treatment	1	not_yet_recruiting
NCT04067960	Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer	No drug interventions	screening	0	completed
NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	No drug interventions	treatment	2	active_not_recruiting
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	No drug interventions	treatment	2	recruiting